Thomas P. Lodise

Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

Michael J. Rybak, Jennifer Lê, Thomas P. Lodise et al. · American Journal of Health-System Pharmacy · 2020 · 1K citations · Full text

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 732 citations

Antimicrobial Susceptibility, Health Sciences, Carbapenem-resistant Gram-negative Bacteria +11

Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteremia

Thomas P. Lodise, Peggy S. McKinnon, Linda Swiderski et al. · Clinical Infectious Diseases · 2003 · 602 citations · Full text

Health Sciences, Antibiotics, Healthcare-associated Infection +15

Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity

Thomas P. Lodise, Ben M. Lomaestro, Jeffrey Graves et al. · Antimicrobial Agents and Chemotherapy · 2008 · 577 citations · Full text

Renal Pathology, Pharmacotherapy, Antimicrobial Chemotherapy +23

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia Treated with Vancomycin

Thomas P. Lodise, Jeffrey Graves, A. Evans et al. · Antimicrobial Agents and Chemotherapy · 2008 · 551 citations · Full text

Mrsa Culture, Mrsa Bacteremia, Antibiotic Resistance +16